June 14, 2024

Salk Institute mourns the loss of John Adler, friend and former trustee

索尔克新闻


Salk Institute mourns the loss of John Adler, friend and former trustee

LA JOLLA—The Salk Institute mourns the loss of businessman and philanthropist John Adler, who served on the Institute’s Board of Trustees from 1991 to 2004. He died June 11, 2024, in Greenwich, Connecticut at the age of 96.

John Adler
John Adler
点击此处 用于高分辨率图像。.
版权:萨克研究所

Adler generously supported the Salk Institute for decades, donating $6.7 million to launch the Adler Foundation Symposium on Alzheimer’s Disease Endowment, establish the Vi and John Adler Chair for Research on Age-Related Neurodegenerative Disease, and support many other research efforts.

For more than 30 years, the annual Adler Symposium brought together scientists working on different aspects of Alzheimer’s disease to share ideas and build new collaborations.

教授 鲁斯蒂·盖奇, former Salk president, currently holds the Vi and John Adler Chair. His team reprograms skin and other cells from patients with neurologic and psychiatric diseases into induced pluripotent stem cells, induced neurons, and organoids. With these tools, they are deciphering the mechanisms that lead to neurological disorders such as Alzheimer's Disease and exploring new therapeutic approaches.

"John was an outstanding trustee for Salk, for many years,” Gage says. “His sage counsel and generosity of time and resources have benefited the Institute immensely. His legacy of the Adler Symposium, focusing on age-related neurodegenerative diseases, has brought international acclaim to the Salk Institute, forging strong bonds and research collaborations around the world. We are grateful that John was part of our community."

Adler’s family asks that donations in his memory be made to the Salk Institute at www.salk.edu/donate.

更多信息

宣传办公室
电话:(858) 453-4100
press@salk.edu

萨尔克生物学研究所

萨尔克研究所是一个独立的非营利性研究机构,由首个安全有效的脊髓灰质炎疫苗的研发者乔纳斯·索尔克于1960年创立。该研究所的使命是推动以合作、敢于冒险为特点的基础性研究,以应对癌症、阿尔茨海默病和农业脆弱性等社会最紧迫的挑战。这项基础科学支撑着所有的转化研究,产生有助于全球新药和创新的见解。.